Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ICCM vs ATEC vs NVCR vs XTNT vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ICCM
IceCure Medical Ltd

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$351M
5Y Perf.-51.0%
ATEC
Alphatec Holdings, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.20B
5Y Perf.-45.3%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.05B
5Y Perf.-86.6%
XTNT
Xtant Medical Holdings, Inc.

Medical - Devices

HealthcareAMEX • US
Market Cap$65M
5Y Perf.-63.5%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$115.36B
5Y Perf.+8.7%

ICCM vs ATEC vs NVCR vs XTNT vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ICCM logoICCM
ATEC logoATEC
NVCR logoNVCR
XTNT logoXTNT
SYK logoSYK
IndustryMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$351M$1.20B$2.05B$65M$115.36B
Revenue (TTM)$4M$595M$674M$122M$25.12B
Net Income (TTM)$-16M$-125M$-173M$2M$3.25B
Gross Margin36.5%89.6%75.2%62.3%63.5%
Operating Margin-8.4%-9.6%-27.2%2.7%22.4%
Forward P/E25.4x15.3x20.1x
Total Debt$217K$620M$290M$29M$14.86B
Cash & Equiv.$9M$161M$103M$17M$4.01B

ICCM vs ATEC vs NVCR vs XTNT vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ICCM
ATEC
NVCR
XTNT
SYK
StockAug 21Jun 26Return
IceCure Medical Ltd (ICCM)10049.0-51.0%
Alphatec Holdings, … (ATEC)10054.7-45.3%
NovoCure Limited (NVCR)10013.4-86.6%
Xtant Medical Holdi… (XTNT)10036.5-63.5%
Stryker Corporation (SYK)100108.7+8.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: ICCM vs ATEC vs NVCR vs XTNT vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 4 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. IceCure Medical Ltd is the stronger pick specifically for recent price momentum and sentiment. ATEC and XTNT also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ICCM
IceCure Medical Ltd
The Momentum Pick

ICCM is the #2 pick in this set and the best alternative if momentum is your priority.

  • +406.8% vs ATEC's -35.5%
Best for: momentum
ATEC
Alphatec Holdings, Inc.
The Long-Run Compounder

ATEC ranks third and is worth considering specifically for long-term compounding.

  • 200.0% 10Y total return vs SYK's 187.6%
  • 25.0% revenue growth vs ICCM's 2.7%
Best for: long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
XTNT
Xtant Medical Holdings, Inc.
The Growth Play

XTNT is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 14.2%, EPS growth 125.0%, 3Y rev CAGR 32.2%
  • Lower volatility, beta 0.70, Low D/E 56.4%, current ratio 2.65x
  • Beta 0.70, current ratio 2.65x
  • Lower P/E (15.3x vs 20.1x)
Best for: growth exposure and sleep-well-at-night
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 16 yrs, beta 0.45, yield 1.1%
  • 12.9% margin vs ICCM's -441.6%
  • Beta 0.45 vs NVCR's 2.24, lower leverage
  • 1.1% yield; 16-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthATEC logoATEC25.0% revenue growth vs ICCM's 2.7%
ValueXTNT logoXTNTLower P/E (15.3x vs 20.1x)
Quality / MarginsSYK logoSYK12.9% margin vs ICCM's -441.6%
Stability / SafetySYK logoSYKBeta 0.45 vs NVCR's 2.24, lower leverage
DividendsSYK logoSYK1.1% yield; 16-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)ICCM logoICCM+406.8% vs ATEC's -35.5%
Efficiency (ROA)SYK logoSYK6.9% ROA vs ICCM's -119.1%, ROIC 11.4% vs -135.6%

ICCM vs ATEC vs NVCR vs XTNT vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ICCMIceCure Medical Ltd

Segment breakdown not available.

ATECAlphatec Holdings, Inc.
FY 2025
Products And Services
100.0%$764M
NVCRNovoCure Limited

Segment breakdown not available.

XTNTXtant Medical Holdings, Inc.
FY 2025
Orthobiologics
54.4%$73M
Spinal Implant
31.6%$42M
License Revenue
14.0%$19M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

ICCM vs ATEC vs NVCR vs XTNT vs SYK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSYKLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

SYK leads this category, winning 4 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 7045.2x ICCM's $4M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to ICCM's -4.4%. On growth, ICCM holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricICCM logoICCMIceCure Medical L…ATEC logoATECAlphatec Holdings…NVCR logoNVCRNovoCure LimitedXTNT logoXTNTXtant Medical Hol…SYK logoSYKStryker Corporati…
RevenueTrailing 12 months$4M$595M$674M$122M$25.1B
EBITDAEarnings before interest/tax-$29M$4M-$165M$8M$6.3B
Net IncomeAfter-tax profit-$16M-$125M-$173M$2M$3.2B
Free Cash FlowCash after capex-$15M$7M-$48M$8M$4.3B
Gross MarginGross profit ÷ Revenue+36.5%+89.6%+75.2%+62.3%+63.5%
Operating MarginEBIT ÷ Revenue-8.4%-9.6%-27.2%+2.7%+22.4%
Net MarginNet income ÷ Revenue-4.4%-21.1%-25.7%+1.5%+12.9%
FCF MarginFCF ÷ Revenue-4.3%+1.2%-7.1%+6.4%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year+25.7%-100.0%+12.3%-36.5%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+6.6%+37.1%-100.0%+56.0%
SYK leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

XTNT leads this category, winning 4 of 6 comparable metrics.

At 15.3x trailing earnings, XTNT trades at a 57% valuation discount to SYK's 35.9x P/E. On an enterprise value basis, XTNT's 6.1x EV/EBITDA is more attractive than ATEC's 3811.2x.

MetricICCM logoICCMIceCure Medical L…ATEC logoATECAlphatec Holdings…NVCR logoNVCRNovoCure LimitedXTNT logoXTNTXtant Medical Hol…SYK logoSYKStryker Corporati…
Market CapShares × price$351M$1.2B$2.0B$65M$115.4B
Enterprise ValueMkt cap + debt − cash$342M$1.7B$2.2B$76M$126.2B
Trailing P/EPrice ÷ TTM EPS-21.75x-8.25x-14.75x15.34x35.86x
Forward P/EPrice ÷ next-FY EPS est.25.41x20.11x
PEG RatioP/E ÷ EPS growth rate2.41x
EV / EBITDAEnterprise value multiple3811.24x6.09x20.75x
Price / SalesMarket cap ÷ Revenue103.91x1.57x3.12x0.48x4.59x
Price / BookPrice ÷ Book value/share36.67x32.99x5.89x1.35x5.13x
Price / FCFMarket cap ÷ FCF431.83x6.35x26.93x
XTNT leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 5 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-4 for ATEC. ICCM carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), XTNT scores 8/9 vs ICCM's 3/9, reflecting strong financial health.

MetricICCM logoICCMIceCure Medical L…ATEC logoATECAlphatec Holdings…NVCR logoNVCRNovoCure LimitedXTNT logoXTNTXtant Medical Hol…SYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-2.1%-4.4%-50.8%+3.7%+15.0%
ROA (TTM)Return on assets-119.1%-15.8%-16.5%+1.9%+6.9%
ROICReturn on invested capital-135.6%-12.6%-16.4%+8.1%+11.4%
ROCEReturn on capital employed-187.2%-13.7%-28.9%+11.2%+13.0%
Piotroski ScoreFundamental quality 0–936586
Debt / EquityFinancial leverage0.02x17.21x0.85x0.56x0.66x
Net DebtTotal debt minus cash-$9M$459M$187M$12M$10.8B
Cash & Equiv.Liquid assets$9M$161M$103M$17M$4.0B
Total DebtShort + long-term debt$217,000$620M$290M$29M$14.9B
Interest CoverageEBIT ÷ Interest expense-313.68x-3.29x-96.80x2.07x6.72x
SYK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ICCM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $12,571 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, ICCM leads with a +406.8% total return vs ATEC's -35.5%. The 3-year compound annual growth rate (CAGR) favors ICCM at 68.6% vs NVCR's -39.8% — a key indicator of consistent wealth creation.

MetricICCM logoICCMIceCure Medical L…ATEC logoATECAlphatec Holdings…NVCR logoNVCRNovoCure LimitedXTNT logoXTNTXtant Medical Hol…SYK logoSYKStryker Corporati…
YTD ReturnYear-to-date+728.6%-61.8%+37.1%-38.7%-13.2%
1-Year ReturnPast 12 months+406.8%-35.5%+7.6%-32.5%-20.4%
3-Year ReturnCumulative with dividends+378.9%-48.5%-78.2%-31.3%+11.9%
5-Year ReturnCumulative with dividends-52.1%-44.0%-91.3%-72.6%+25.7%
10-Year ReturnCumulative with dividends-52.1%+200.0%+51.4%-98.2%+187.6%
CAGR (3Y)Annualised 3-year return+68.6%-19.9%-39.8%-11.8%+3.8%
ICCM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NVCR and SYK each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than NVCR's 2.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 93.5% from its 52-week high vs ATEC's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricICCM logoICCMIceCure Medical L…ATEC logoATECAlphatec Holdings…NVCR logoNVCRNovoCure LimitedXTNT logoXTNTXtant Medical Hol…SYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.85x0.64x2.24x0.70x0.45x
52-Week HighHighest price in past year$5.69$23.29$19.25$0.95$404.87
52-Week LowLowest price in past year$0.13$6.82$9.82$0.44$281.00
% of 52W HighCurrent price vs 52-week peak+91.7%+34.0%+93.5%+48.4%+74.4%
RSI (14)Momentum oscillator 0–10023.139.349.139.238.2
Avg Volume (50D)Average daily shares traded1.2M3.3M1.5M158K2.3M
Evenly matched — NVCR and SYK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ATEC as "Buy", NVCR as "Buy", SYK as "Buy". Consensus price targets imply 148.9% upside for ATEC (target: $20) vs 28.1% for SYK (target: $386). SYK is the only dividend payer here at 1.12% yield — a key consideration for income-focused portfolios.

MetricICCM logoICCMIceCure Medical L…ATEC logoATECAlphatec Holdings…NVCR logoNVCRNovoCure LimitedXTNT logoXTNTXtant Medical Hol…SYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$19.71$33.50$385.83
# AnalystsCovering analysts181550
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises16
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+0.1%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

SYK leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XTNT leads in 1 (Valuation Metrics). 1 tied.

Best OverallStryker Corporation (SYK)Leads 2 of 6 categories
Loading custom metrics...

ICCM vs ATEC vs NVCR vs XTNT vs SYK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ICCM or ATEC or NVCR or XTNT or SYK a better buy right now?

For growth investors, Alphatec Holdings, Inc.

(ATEC) is the stronger pick with 25. 0% revenue growth year-over-year, versus 2. 7% for IceCure Medical Ltd (ICCM). Xtant Medical Holdings, Inc. (XTNT) offers the better valuation at 15. 3x trailing P/E, making it the more compelling value choice. Analysts rate Alphatec Holdings, Inc. (ATEC) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ICCM or ATEC or NVCR or XTNT or SYK?

On trailing P/E, Xtant Medical Holdings, Inc.

(XTNT) is the cheapest at 15. 3x versus Stryker Corporation at 35. 9x. On forward P/E, Stryker Corporation is actually cheaper at 20. 1x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — ICCM or ATEC or NVCR or XTNT or SYK?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +25.

7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ATEC returned +200. 0% versus XTNT's -98. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ICCM or ATEC or NVCR or XTNT or SYK?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

45β versus NovoCure Limited's 2. 24β — meaning NVCR is approximately 392% more volatile than SYK relative to the S&P 500. On balance sheet safety, IceCure Medical Ltd (ICCM) carries a lower debt/equity ratio of 2% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ICCM or ATEC or NVCR or XTNT or SYK?

By revenue growth (latest reported year), Alphatec Holdings, Inc.

(ATEC) is pulling ahead at 25. 0% versus 2. 7% for IceCure Medical Ltd (ICCM). On earnings-per-share growth, the picture is similar: Xtant Medical Holdings, Inc. grew EPS 125. 0% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, XTNT leads at 32. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ICCM or ATEC or NVCR or XTNT or SYK?

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -445. 6% for IceCure Medical Ltd — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -446. 7% for ICCM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ICCM or ATEC or NVCR or XTNT or SYK more undervalued right now?

On forward earnings alone, Stryker Corporation (SYK) trades at 20.

1x forward P/E versus 25. 4x for Alphatec Holdings, Inc. — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 148. 9% to $19. 71.

08

Which pays a better dividend — ICCM or ATEC or NVCR or XTNT or SYK?

In this comparison, SYK (1.

1% yield) pays a dividend. ICCM, ATEC, NVCR, XTNT do not pay a meaningful dividend and should not be held primarily for income.

09

Is ICCM or ATEC or NVCR or XTNT or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 1. 1% yield, +187. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 6%, NVCR: +51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ICCM and ATEC and NVCR and XTNT and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICCM is a small-cap quality compounder stock; ATEC is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; XTNT is a small-cap deep-value stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while ICCM, ATEC, NVCR, XTNT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ICCM

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Gross Margin > 21%
Run This Screen
Stocks Like

ATEC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 53%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

XTNT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 37%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ICCM and ATEC and NVCR and XTNT and SYK on the metrics below

Revenue Growth>
%
(ICCM: 25.7% · ATEC: -100.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.